TrialCancer research communications2025

A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Dejan Juric et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.